Late gadolinium enhancement on cardiac magnetic resonance combined with 123I- metaiodobenzylguanidine scintigraphy strongly predicts long-term clinical outcome in patients with dilated cardiomyopathy.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 04 01 2019
accepted: 20 05 2019
entrez: 21 6 2019
pubmed: 21 6 2019
medline: 15 2 2020
Statut: epublish

Résumé

Late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) is limited in its ability to detect diffuse interstitial fibrosis, which is commonly found in idiopathic dilated cardiomyopathy (DCM). On the other hand, Washout rate (WR) by cardiac 123I- metaiodobenzylguanidine (123I-MIBG) scintigraphy which evaluates cardiac sympathetic nervous function, is a useful tool for predicting the prognosis in DCM. We investigated the predictive value of the combination of two different types of examinations, LGE on CMR and WR by 123I-MIBG scintigraphy for outcomes in DCM compared with LGE alone. One-hundred forty-eight DCM patients underwent CMR and 123I-MIBG scintigraphy. Patients were divided into 4 groups according to the presence or absence of LGE and WR cut-off value of 45% for predicting prognosis based on receiver operating characteristic curve analysis. Cardiac deaths, re-hospitalization for heart failure, implantation of a left ventricular assist device, and life-threatening ventricular arrhythmias were defined as clinical events. Forty-two DCM patients reached the clinical events during the median follow-up for 9.1 years (interquartile range, 8.0-9.2 years).Multivariable Cox regression analysis identified WR≥45%+LGE positive group as an independent predictor of cardiac events (HR 3.18, 95%CI 1.36-7.45, p = 0.008). Notably, there was no significance in the cardiac event-free survival rate between the WR<45%+LGE positive and WR≥45%+LGE negative groups (p = 0.89). The combination of WR by 123I-MIBG scintigraphy and LGE on CMR, which evaluate different type of cardiac deterioration, serves as a stronger predictor of long-term outcomes in DCM patients than LGE alone.

Identifiants

pubmed: 31220100
doi: 10.1371/journal.pone.0217865
pii: PONE-D-18-37091
pmc: PMC6586397
doi:

Substances chimiques

Contrast Media 0
Iodine Radioisotopes 0
3-Iodobenzylguanidine 35MRW7B4AD
Iodine-123 8YWR746RPQ
Gadolinium AU0V1LM3JT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0217865

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Am Coll Cardiol. 1988 Nov;12(5):1252-8
pubmed: 3170968
J Am Coll Cardiol. 1995 Dec;26(7):1594-9
pubmed: 7594091
J Med Invest. 2006 Feb;53(1-2):95-102
pubmed: 16538001
Jpn Circ J. 2001 Mar;65(3):155-60
pubmed: 11266187
JACC Heart Fail. 2017 Jan;5(1):28-38
pubmed: 28017348
Circulation. 2002 Oct 29;106(18):2322-7
pubmed: 12403661
J Nucl Cardiol. 1998 Nov-Dec;5(6):579-90
pubmed: 9869480
Eur Heart J. 2008 May;29(9):1147-59
pubmed: 18349024
Circ Cardiovasc Imaging. 2014 Mar;7(2):250-258
pubmed: 24363358
JACC Cardiovasc Imaging. 2013 Jul;6(7):772-84
pubmed: 23845574
J Am Coll Cardiol. 2011 Feb 22;57(8):891-903
pubmed: 21329834
Eur J Heart Fail. 2010 Mar;12(3):227-31
pubmed: 20156939
Heart. 2001 Dec;86(6):701-8
pubmed: 11711472
Int Heart J. 2012;53(5):282-6
pubmed: 23038088
Ann Nucl Med. 2011 Jul;25(6):419-24
pubmed: 21461599
Circulation. 1996 Mar 1;93(5):841-2
pubmed: 8598070
J Am Coll Cardiol. 2010 Jun 15;55(24):2769-77
pubmed: 20538172
J Am Coll Cardiol. 2006 Nov 21;48(10):1977-85
pubmed: 17112987
J Nucl Med. 2009 Jan;50(1):61-7
pubmed: 19091900
J Cardiovasc Magn Reson. 2006;8(3):417-26
pubmed: 16755827
Immunology. 2006 May;118(1):10-24
pubmed: 16630019
Ann Nucl Med. 2002 Sep;16(6):387-93
pubmed: 12416577
J Nucl Med. 1992 Apr;33(4):471-7
pubmed: 1552326
Circulation. 2005 May 31;111(21):2837-49
pubmed: 15927992
Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):262-70
pubmed: 23096078
Arq Bras Cardiol. 2013 Jul;101(1):4-8
pubmed: 23917506
Circulation. 2003 Sep 23;108(12):1499-505
pubmed: 12952842
J Nucl Med. 1999 Jun;40(6):917-23
pubmed: 10452306

Auteurs

Misato Chimura (M)

Himeji Cardiovascular Center, Himeji, Japan.

Shinichiro Yamada (S)

Himeji Cardiovascular Center, Himeji, Japan.

Yasuyo Taniguchi (Y)

Himeji Cardiovascular Center, Himeji, Japan.

Yoshinori Yasaka (Y)

Himeji Cardiovascular Center, Himeji, Japan.

Hiroya Kawai (H)

Himeji Cardiovascular Center, Himeji, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH